Track Takeda Pharmaceutical's common stock ($1.7T) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
As of the most recent data (June 2026), TAK shows a common stock of $1.7T. That compares with $1.7T in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TAK's common stock is now $1.7T (was $1.7T) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Takeda Pharmaceutical is outperforming or lagging.
Tracking TAK's common stock over time shows whether Takeda Pharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $1.7T That compares with $1.7T in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this common stock page, Stockcircle has Takeda Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $1.7T) with ownership activity and broader fundamentals.
Takeda Pharmaceutical's common stock is $1.7T; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.